STUDY QUESTION: How well does multi-analyte steroid mass spectrometry (MS) profiling classify women with and without polycystic ovary syndrome (PCOS)?
Introduction
Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder of reproductive aged women with a prevalence of 9-18% (March et al., 2010) and constitutes a major burden on health, medical care and costs (Dumesic et al., 2015) . Androgen excess is the most common clinical manifestation and a key defining diagnostic feature. However, serum testosterone measured by direct (non-extraction) immunoassays displays an overlap between women with and without PCOS limiting its diagnostic potential. As non-extraction testosterone assays in women are less accurate and display method-specific bias relative to liquid chromatography-mass spectrometry (LC-MS) measurements (Handelsman and Wartofsky, 2013) , we have evaluated the performance of multi-analyte LC-MS serum steroid profiling measuring nine ovarian and adrenal steroids for discrimination between women with and without PCOS and compared it with immunoassays for testosterone and sex hormone binding globulin (SHBG) together with the calculated free androgen index (FAI).
Materials and Methods

Study participants
We analysed biobanked samples from baseline measurements of three clinical trials (Meyer et al., 2005; Moran et al., 2011; Lambert et al., 2015) of premenopausal women with (n = 178) and without (n = 62) PCOS diagnosed by Rotterdam criteria. Serum samples were available for this analysis from 152 and 45 women, respectively. The excluded women who had PCOS were heavier, with higher BMI and waist circumference and 2 hr post-glucose blood glucose and insulin than those included while the excluded controls were younger but all other variables did not differ between the included and excluded women. The women studied were aged 18-45 years and overweight or obese (BMI >25 kg/m 2 ). For two studies (Meyer et al., 2005; Moran et al., 2011) , the controls had no history of diagnosed PCOS and were included because they did not meet the criteria for PCOS. If presenting with hyperandrogenism or menstrual irregularity then ultrasound was performed to exclude PCO, defined by 12 or more follicles in each ovary measuring 2-9 mm in diameter, and/or increased ovarian volume (>10 ml) (Balen et al., 2003) . For the third study (Lambert et al., 2015) , control women reported regular menstrual cycles, with no biochemical or clinical hyperandrogenism. Exclusion criteria were diabetes mellitus, pregnancy, breastfeeding, hypertension, cardiovascular, cerebrovascular, liver diseases, severely impaired renal function, severe mental illness and endocrine disorders (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, hyperprolactinaemia, thyroid dysfunction and adrenal disorders). All participants ceased insulinsensitizing or reproductive hormonal medication for at least 3 months prior to baseline measurements.
Clinical and reproductive hormone measurement
Following an overnight fast, height, weight (lightly clothed, no shoes), waist circumference, and resting systolic and diastolic blood pressure were measured; a modified (nine site) Ferriman-Gallwey (FG) hirsutism score was assessed; BMI was calculated; and morning (08:00-11:00) venous blood samples were taken for analysis of glucose, insulin, highly sensitive C-reactive protein (hsCRP) and lipids (total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides) as well as steroid profile. An oral 75 gm glucose tolerance test was performed with serum insulin and glucose measured at 120 min and homeostasis assessment of insulin resistance was calculated by [(fasting insulin) × (fasting glucose)]/22.5. Total testosterone (T_IA) was measured by chemiluminescent immunoassay (Beckman Coulter, Fullerton, CA) with intra-and inter-assay coefficients of variation of 1.67% and 4.78%, respectively. SHBG was measured by chemiluminescent immunoassay (Immulite 1000, EURO/Diagnostics Products Corp. Ltd., Los Angeles, CA or Beckman Coulter Unicel DXI 800, Beckman Coulter, Lane
Cove, NSW, Australia). Routine clinical chemistry analytes were measured within 24 hr of the sample being obtained and serum was stored at −80°C until LC-MS steroid analysis. Serum testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), androstenedione (A 4 ), estradiol (E 2 ), estrone (E 1 ), 17 hydroxy progesterone (17OHP 4 ), progesterone (P 4 ) and cortisol were measured in liquid:liquid extracts (methyl tertiary-butyl ether) of serum (0.2 ml) by liquid chromatography-tandem mass spectrometry (LC-MS-MS) as described (Harwood and Handelsman, 2009 ) with modifications for an expanded steroid profile and incorporating ultra-pressure liquid chromatography (Keski-Rahkonen et al., 2015) . Steroid measurements were calibrated against certified reference materials for T and DHT (National Measurement Institute, North Ryde, Australia), E 2 (European Commission's Institute for Reference Materials and Measurements) and E 1 (Cerilliant Corporation) and against pure standards where certified reference materials were not available (DHEA, P 4 , 17OHP 4 and cortisol). The assay characteristics (limit of quantification according to established FDA/ EMEA criteria (EMEA, 2011; FDA CDER, 2013) , extraction recovery and coefficient of variation of quality control specimens) are listed in Supplementary data, Table S1 . For testosterone measurements below the limit of quantitation, concentrations were imputed as 0.5 times the lower limit of quantification for data analysis.
Calculated free testosterone (cFT) levels were computed using an empirical formula validated in two large data sets comprising over 6000 blood samples (Sartorius et al., 2009; Ly et al., 2010) . FAI was calculated from serum T_IA measurement divided by serum SHBG and expressed as a percentage. In order to define net androgen status, we also evaluated an exploratory variable defined as total androgen index (TAI) which is the sum of serum T concentration plus five times serum DHT concentration Hsu et al., 2015) .
Statistical analyses
Differences between women with and without PCOS were tested by a two-sample t-test assuming unequal variance. Discrimination was investigated by C-statistics (area-under-curve of receiver operator curve plots of sensitivity versus specificity) defined by logistic regression using forward stepping models that minimize log-likelihood with individual predictors evaluated by Wald statistics. FAI was not included in models that included serum T or SHBG due to collinearity. Sensitivity, specificity, positive and negative predictive values were defined conventionally from a 2 × 2 table of predictions for variable(s) compared with the known diagnosis of PCOS and control groups. Correlation between immunoassay and LC-MS measurements of serum T was by Passing-Bablok and linear regression. Data were analysed using NCSS version 10 (NCSS, LLC. Kaysville, Utah, USA; 2015), Medcalc version 15 (Ostend, Belgium; 2015) and SPSS version 22 (IBM Corp, Armonk, NY, USA; 2015).
Ethics approval
The studies received ethics approval from Monash University, Southern Health or the Alfred Hospital Human Ethics Committees and all participants gave written informed consent.
Results
Women with PCOS were younger and heavier, and had larger waist circumferences, higher blood pressures and higher FG scores as well as higher hsCRP, HOMA scores and triglyceride levels but no differences in fasting glucose or cholesterol profiles non-PCOS women. Women with PCOS also had higher serum T, DHEA, A 4 , T_IA, cFT, FAI and TAI and lower E 2 but no differences in serum DHT, E 1 , P 4 , 17OHP 4 or cortisol (Supplementary data, Table SII) . For hormonal variables, the highest univariate C-statistics were FAI (0.89) and T_IA (0.82), with the remainder of other variables between 0.40 and 0.76 (Supplementary data, Table SII ).
The serum testosterone immunoassay (T_IA) had a significant upward bias (overall mean bias >100%) relative to LC-MS measurement (Supplementary data, Fig. S1 ) with a slope of 1.86 (95% CI 1.59-2.18) and intercept 0.02 (−0.08 to 0.10). The upward bias was most pronounced below serum testosterone of 0.5 ng/ml (1.7 nmol/l), a range including >80% of samples (n = 164, slope = 1.99, 95% CI 1.85, 2.13) compared with samples with serum testosterone >0.5 ng/ml (n = 32, slope = 1.14, 95% CI 1.0, 1.29).
A summary of the optimal classification models is listed in Table I with details in Supplementary data, Table SIII . Model 1 included all direct steroid LC-MS measurements together with serum SHBG and derivatives of those measurements, notably serum TAI and cFT. Model 1 had good positive (85%) and negative (75%) predictive values and high sensitivity (96%) but relatively low specificity (43%) with an overall correct prediction of 84% (Supplementary data, Table SII ). In Model 2, replacing serum T by MS with measurement by immunoassay (T_IA) marginally reduced all of the discrimination statistics. Model 3 replaced cFT and SHBG with FAI and marginally improved the positive predictive value (85-89%) but reduced the negative predictive value (76-47%) and specificity (43-28%) without a change in sensitivity or overall correct prediction. Finally, combining the changes in Models 2 and 3 into Model 4, marginally improved the positive predictive value but reduced the negative predictive value without change in overall correct prediction. Adding into the models age or measures of obesity (weight, waist circumference, BMI) led to inclusion of serum E 2 in the optimal classification but did not otherwise change the set of effective predictor variables (data not shown). All models showed no significant improvement over a single measurement of testosterone by immunoassay or LC-MS.
Discussion
This study provides insight into the utility and limitations of steroid mass spectrometry to aid PCOS diagnosis by discriminating between women with and without PCOS. Despite MS measurement of nine ovarian or adrenal steroids, the optimal discrimination model remained unable to completely distinguish between women with and without PCOS. That optimal discrimination was achieved with a combination of serum A 4 , DHEA and SHBG after evaluating but discarding serum T, DHT, DHEA, E 2 , E 1 , 17OHP 4 , P 4 and cortisol.
Previous studies evaluating the diagnostic impact for PCOS of MS multi-analyte serum steroid profiling (Barth et al., 2010; Legro et al., 2010; Janse et al., 2011; Salameh et al., 2014) have highlighted the utility of measuring DHT (Munzker et al., 2015) , A 4 (O'Reilly et al., 2014), estrone (Stener-Victorin et al., 2010) and of wide steroid profiling (Keefe et al., 2014) . Nevertheless, even including all these analytes in a wide profile of unconjugated steroids, the present findings with a large sample size do not confirm any improvement of LC-MS steroid profile over direct T_IA and FAI in discriminating between women with and without PCOS. This is consistent with contemporary clinical practice guidelines Legro et al., 2013; Conway et al., 2014) which recommend such conventional immunoassay-based measurements, despite their suboptimal biochemical accuracy or confirmation of PCOS diagnosis.
Direct T_IA displayed consistently higher concentrations than MS measurements, confirming previous studies showing a method-specific, usually upward, bias of direct T_IAs relative to MS-based testosterone measurement (Taieb et al., 2003; Sikaris et al., 2005) including in women with PCOS without (Legro et al., 2010; Keefe et al., 2014) or with (Janse et al., 2011; Salameh et al., 2014) pre-immunoassay solvent extraction. Nevertheless, T_IA displayed a higher discrimination (C-statistics) in univariate and multivariate models between PCOS and control women. These discrepancies between assay methodologies probably reflect the impact on the T_IA of cross-reactivity from unidentified but structurally related steroids such as Phase II conjugated steroid metabolites (Labrie et al., 2006) . These are removed by solvent extraction and chromatography prior to MS measurement but may still impact on direct T_IAs. Further studies are warranted to identify whether measurement of Phase I or II androgen metabolites provides greater biochemical discrimination for PCOS diagnosis. The present study confirms the decreased or unchanged serum DHT (Munzker et al., 2015; Stener-Victorin et al., 2010) and increased serum A 4 (Barth et al., 2010; Stener-Victorin et al., 2010; Janse et al., 2011; Keefe et al., 2014) concentrations in PCOS but without supporting that their measurement improves overall biochemical diagnosis of PCOS (O'Reilly et al., 2014) .
The limitations of this study include its origin in pooling biobanked baseline samples from three different clinical studies of Australian women in which not all women had ovarian ultrasound unless required for diagnosis. Although the studies employed consistent clinical procedures, overlapping staff and the same MS-based measurements, nevertheless our findings may be affected by participation bias and may not be generalizable to all other PCOS populations, notably for different ethnic or geographic origins and different referral patterns or selection pressures. Similarly, the findings using the direct T_IAs used in this study may not extrapolate to all other T_IAs.
In conclusion, despite LC-MS providing a reference level of specificity coupled with high sensitivity and multi-analyte capability for measurement of nine ovarian and adrenal steroids from small, single serum samples, the present study suggests that the clinical diagnostic utility of LC-MS steroid profile is not better in discriminating between women with and without PCOS compared with the T_IA and FAI as advocated by extant clinical guidelines. This may reflect the non-homogeneity of the presumptive clinical diagnosis or else that the steroids measured in this study do not yet include the best markers. For example, other prohormone precursors and/or metabolites not measured in this study may still provide better discrimination and such further studies are warranted.
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